The present invention relates to novel compositions comprising specific consortia of living bacteria strains； to the manufacturing of such compositions, particularly by co-cultivation； and to the use of such compositions in pharmaceutical applications, such as the treatment of diseases associated with intestinal microbiota dysbiosis, particularly intestinal infections such as CDI (Clostridium difficile infection) and IBD (Inflammatory bowel diseases). When compared to the traditional FMT therapy, the inventive compositions are more efficient and safer as demonstrated on an acute colitis model and therefore more appropriate for therapeutic use.
